Literature DB >> 11741394

Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice.

L S Kulnane1, B T Lamb.   

Abstract

Mutations in the amyloid precursor protein (APP) gene result in elevated production and deposition of the 42 amino acid beta-amyloid (Abeta1-42) peptide and early-onset Alzheimer's disease (AD). To accurately examine the effect of the APP FAD mutations in vivo, we introduced yeast artificial chromosomes (YACs) containing the entire genomic copy of human APP harboring FAD mutations into transgenic mice. Our current results demonstrate that mutant APP YAC transgenic mice exhibit many features characteristic of human AD, including regional deposition of Abeta with preferential deposition of Abeta1-42, extensive neuritic abnormalities as evidenced by staining with APP, ubiquitin, neurofilament, and hyperphosphorylated tau antibodies, increased markers of inflammation, and the overlapping deposition of Abeta with apolipoproteins E and J. Our results also suggest that APP YAC transgenic mice possess unique pathological attributes when compared to other transgenic mouse models of AD that may reflect the experimental design of each model.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11741394     DOI: 10.1006/nbdi.2001.0446

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  17 in total

1.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.

Authors:  Sungho Lee; Nicholas H Varvel; Megan E Konerth; Guixiang Xu; Astrid E Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

Review 2.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

3.  Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-β Protein Precursor Transgenic Mice.

Authors:  Peng Liu; John H Reichl; Eshaan R Rao; Brittany M McNellis; Eric S Huang; Laura S Hemmy; Colleen L Forster; Michael A Kuskowski; David R Borchelt; Robert Vassar; Karen H Ashe; Kathleen R Zahs
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain.

Authors:  Tsuyoshi Hamaguchi; Yvonne S Eisele; Nicholas H Varvel; Bruce T Lamb; Lary C Walker; Mathias Jucker
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

5.  Creation and characterization of BAC-transgenic mice with physiological overexpression of epitope-tagged RCAN1 (DSCR1).

Authors:  Luzhou Xing; Martha Salas; Hong Zhang; Julia Gittler; Thomas Ludwig; Chyuan-Sheng Lin; Vundavalli V Murty; Wayne Silverman; Ottavio Arancio; Benjamin Tycko
Journal:  Mamm Genome       Date:  2012-10-25       Impact factor: 2.957

6.  NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease.

Authors:  Nicholas H Varvel; Kiran Bhaskar; Maria Z Kounnas; Steven L Wagner; Yan Yang; Bruce T Lamb; Karl Herrup
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

7.  Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease.

Authors:  Tatiana Melnikova; DaMin Park; Lauren Becker; Deidre Lee; Eugenia Cho; Nuzhat Sayyida; Jing Tian; Karen Bandeen-Roche; David R Borchelt; Alena V Savonenko
Journal:  Neurobiol Dis       Date:  2016-08-26       Impact factor: 5.996

8.  Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.

Authors:  Matthew J Chiocco; Laura Shapiro Kulnane; Linda Younkin; Steve Younkin; Geneviève Evin; Bruce T Lamb
Journal:  J Biol Chem       Date:  2004-09-27       Impact factor: 5.157

Review 9.  Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease.

Authors:  Gjumrakch Aliev; Mark A Smith; Mark E Obrenovich; Jack C de la Torre; George Perry
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice.

Authors:  Gehad M Subaiea; Lina I Adwan; Aseef H Ahmed; Karen E Stevens; Nasser H Zawia
Journal:  Neurobiol Aging       Date:  2013-04-30       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.